🇺🇸 FDA
Patent

US 11660318

Use of adipose tissue-derived stromal stem cells in treating fistula

granted A61KA61K35/12A61K35/35

Quick answer

US patent 11660318 (Use of adipose tissue-derived stromal stem cells in treating fistula) held by Takeda Pharmaceutical Company Limited expires Mon May 25 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Takeda Pharmaceutical Company Limited
Grant date
Tue May 30 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 25 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
15
CPC classes
A61K, A61K35/12, A61K35/35, A61K45/06, A61P